SCHEMBL30666042

SCHEMBL30666042

COc1c(F)cc(C(=O)O)c(C)c1OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.43
TDP1 Q9NUW8 2/20 0.40
LMNA P02545 1/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
RAB9A P51151 1/20 0.40
MAPT P10636 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
KDM4E B2RXH2 2/20 0.39
PKM P14618 1/20 0.38
KEAP1 Q14145 1/20 0.38
NFE2L2 Q16236 1/20 0.38
LCK P06239 1/20 0.38
FYN P06241 1/20 0.38
CD274 Q9NZQ7 1/20 0.37
FFAR1 O14842 1/20 0.37
FFAR4 Q5NUL3 1/20 0.37
TUBB1 Q9H4B7 2/20 0.36
ALDH1A1 P00352 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18186481 0.87 HSD17B10 (0.42) HSD17B10TDP1LMNAMAPK1HTT
SCHEMBL27540803 0.85 HSD17B10 (0.50) HSD17B10TDP1LMNAMAPK1HTT
SCHEMBL18393916 0.84 KDM4E (0.44) HSD17B10TDP1LMNARAB9AMAPT
SCHEMBL28424948 0.83 HSD17B10 (0.44) HSD17B10TDP1LMNAMAPK1HTT
SCHEMBL27731624 0.82 HSD17B10 (0.52) HSD17B10TDP1MAPTMEN1KMT2A
SCHEMBL15573104 0.81 HSD17B10 (0.46) HSD17B10TDP1MAPTMEN1KMT2A
SCHEMBL31012417 0.81 HSD17B10 (0.46) HSD17B10TDP1MAPTMEN1KMT2A
SCHEMBL670626 0.79 TPMT (0.49) HSD17B10TDP1HTTMAPTMEN1
SCHEMBL6422815 0.79 HSD17B10 (0.44) HSD17B10TDP1LMNAMAPK1HTT
SCHEMBL4903560 0.79 PKM (0.58) HSD17B10TDP1LMNAMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250320222-A1 TRICYCLIC COMPOUNDS AND USES THEREOF HUTCHMED LTD (CN) 2025-10-16 US disclosed
EP-4532500-A1 TRICYCLIC COMPOUNDS AND USES THEREOF HUTCHMED Limited (CN) 2025-04-09 EP disclosed
CN-119301129-A Tricyclic compounds and uses thereof 和记黄埔医药(上海)有限公司 2025-01-10 CN disclosed
WO-2023232025-A1 TRICYCLIC COMPOUNDS AND USES THEREOF HUTCHMED LIMITED (CN) 2023-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250320222-A1 TRICYCLIC COMPOUNDS AND USES THEREOF CYP11B2, CYP11B1, CYP3A7 HSD17B10 201/4885TDP1 979/4885LMNA 1612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.